AccessibilityHelpAbout Us
Eom Pharmaceuticals logo

Eom Pharmaceuticals(OTC) IMUC

Market Cap$20.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-68%
5 Year-71%
1 Year+276%
1 Month+16%
$0.16
-10.19%
-0.02Today
Eom Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.162026-09-17
Eom Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.57%USD 0.152026-09-10
1 month+15.79%USD 0.142026-08-18
3 month-22.91%USD 0.212026-06-18
Year to date+128.31%USD 0.072025-12-31
1 year+276.1%USD 0.042025-09-17
3 year-42.11%USD 0.282023-09-18
5 year-70.53%USD 0.552021-09-17
Since inception-68.22%USD 0.512021-12-03

Eom Pharmaceuticals Financials at a Glance

Market Cap

$20.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$2.65M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-0.00 (Low)

Price

$0.16

Volume

333

Open

$0.16

Previous Close

$0.16

Daily Range

$0.16 - $0.16

52-Week Range

$0.04 - $0.34

Estimated Earnings Date

N/A

IMUC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eom Pharmaceuticals

EOM Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology company dedicated to developing innovative drugs aimed at transforming therapeutic paradigms for patients with debilitating diseases. The company focuses on enhancing the quality of life for individuals suffering from conditions such as cancer cachexia, HIV/AIDS, and age-related macular degeneration.

Products and Services
  • EOM613: A peptide nucleic-acid solution targeting cancer cachexia and infectious diseases
  • EOM 147: An investigational aminosterol for age-related macular degeneration
  • Research and development of therapies for various debilitating diseases
Growth Outlook
  • Ongoing Phase 2 trials for EOM613 and EOM 147 demonstrate strong potential
  • Expansion into infectious disease treatment, including COVID-19, enhances market opportunities
  • Strategic focus on unmet medical needs positions the company for future growth
Financial Highlights
  • Recent quarterly net income of -$464,525 reflects ongoing investment in R&D
  • Cash and cash equivalents increased to $613,244 in Q4 2022
  • Trailing twelve months (TTM) P/E ratio of -9.93 indicates potential for future profitability
EOM Pharmaceuticals Holdings, Inc. is positioned in the biotechnology sector, focusing on innovative solutions for serious health conditions. The company's lead compounds, EOM613 and EOM 147, have shown promise in clinical trials, which may lead to significant advancements in treatment options. The financial data indicates a commitment to research and development, with recent investments aimed at expanding therapeutic applications. The growth outlook remains optimistic, driven by ongoing clinical trials and a strategic focus on addressing unmet medical needs in the healthcare market.
AI Generated • Sep 8, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Irach B. Taraporewala, PhD

Website

www.eompharma.com

Headquarters

Montvale, NJ 07645, US

IMUC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

127.66%

Return on Capital

N/A

Return on Assets

-1933.07%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$20.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

126.50M

Volume

333

Avg. Volume

1.25K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$2.89M

EBITDA

-$2.29M

Operating Cash Flow

-$689.34K

Capital Expenditure

$0.00

Free Cash Flow

-$689.34K

Cash & ST Invst.

$613.24K

Total Debt

$3.47M

Eom Pharmaceuticals Performance Analysis

Eom Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Eom Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-03-31N/A
Q22022-06-30N/A
Q32022-09-30N/A
Q42022-12-31N/A
Eom Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.02-60.3%
20232023-12-31USD -0.02-35.0%
20242024-12-31USD -0.027.9%
20252025-12-31USD -0.02-7.3%
Eom Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-03-3190.6%
Q22022-06-3018.8%
Q32022-09-30-19.6%
Q42022-12-3138.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2022YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$20.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.84M

N/A

Employees

3

N/A

Net Income

-$464.53K

-15671.9%

EBITDA

-$315.40K

N/A

Quarterly Fundamentals

Name
Q4 2022YOY CHG

Total Cash

$613.24K

+4897.5%

Total Debt

$3.47M

+188.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$619.94K

-48.4%

Short Term Debt

$2.85M

N/A

Return on Assets

-19.33%

N/A

Return on Invested Capital

1.70%

N/A

Free Cash Flow

-$687.93K

N/A

Operating Cash Flow

-$687.93K

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LVCLFAlgorae Pharmaceuticals Limited
$0.01+0.00%
DVHGFDevonian Health Group Inc.
$5.88+0.00%
PRVCFPreveCeutical Medical Inc.
$0.01-10.22%
NYMXFNymox Pharmaceutical Corporation
$0.02+9900.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$44.99-10.22%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$114.82+10.44%
INTCIntel
$108.80+7.67%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$38.53-5.12%

Questions About IMUC

What is the current price of Eom Pharmaceuticals?

Eom Pharmaceuticals is trading at $0.16 per share.

What is the 52-week range for Eom Pharmaceuticals?

Over the past 52 weeks, Eom Pharmaceuticals has traded between $0.04 and $0.34.

How much debt does Eom Pharmaceuticals have?

As of the most recent reporting period, Eom Pharmaceuticals reported total debt of $1.76M.

How much cash does Eom Pharmaceuticals have on hand?

Eom Pharmaceuticals reported $29.76K in cash and cash equivalents in its most recent financial results.

What is Eom Pharmaceuticals’s dividend yield?

Eom Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services